News Column

Researchers at Sojo University Target Human Serum Albumin

June 4, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Human Serum Albumin. According to news reporting originating from Kumamoto, Japan, by NewsRx correspondents, research stated, "Overdoses of acetaminophen (APAP) are a major cause of acute liver failure. N-Acetylcysteine (NAC) is the standard therapy for patients with such an overdose because oxidative stress plays an important role in the pathogenesis of APAP-induced hepatitis."

Our news editors obtained a quote from the research from Sojo University, "However, NAC is not sufficiently efficacious. We previously developed a recombinant human serum albumin (HSA)-thioredoxin 1 (Trx) fusion protein (HSA-Trx), designed to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx, an endogenous protein with antioxidative and anti-inflammatory properties. In this study, we investigated the therapeutic impact of HSA-Trx in mice with APAP-induced hepatitis. The systemic administration of HSA-Trx significantly improved the survival rate of mice treated with a lethal dose of APAP compared with saline. HSA-Trx strongly attenuated plasma transaminases in APAP-induced hepatitis mice compared with HSA or Trx, components of the fusion protein. HSA-Trx also markedly caused a diminution in the histopathological features of hepatic injuries and the number of apoptosis-positive hepatic cells. In addition, an evaluation of oxidative stress markers and plasma cytokine and chemokine levels clearly showed that HSA-Trx significantly improved the breakdown of hepatic redox conditions and inflammation caused by the MAP treatment. HSA-Trx also significantly decreased oxidative and nitrosative/nitrative stress induced by SIN-1 in vitro. Finally, HSA-Trx, but not the NAC treatment at 4 h after APAP injection, significantly inhibited the elevation in plasma transaminase levels."

According to the news editors, the research concluded: "The findings suggest that HSA-Trx has considerable potential for use as a novel therapeutic agent for APAP-induced hepatitis, due to its long-lasting antioxidative and anti-inflammatory effects."

For more information on this research see: Albumin Fusion Prolongs the Antioxidant and Anti-Inflammatory Activities of Thioredoxin in Mice with Acetaminophen-Induced Hepatitis. Molecular Pharmaceutics, 2014;11(4):1228-1238. Molecular Pharmaceutics can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)

The news editors report that additional information may be obtained by contacting R. Tanaka, Sojo Univ, DDS Res Inst, Nishi Ku, Kumamoto 8600082, Japan. Additional authors for this research include Y. Ishima, H. Maeda, A. Kodama, S. Nagao, H. Watanabe, V.T.G. Chuang, M. Otagiri and T. Maruyama (see also Human Serum Albumin).

Keywords for this news article include: Asia, Antioxidants, Japan, Kumamoto, Proteins, Hepatitis, Acetanilides, Therapeutics, Thioredoxins, Acetaminophen, Liver Diseases, Gastroenterology, Protective Agents, Infectious Disease, Human Serum Albumin, Digestive System Diseases

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters